In recent developments within pediatric HIV research, a pivotal study has emerged focusing on iron metabolism, absorption, and supplementation efficacy in children living with virally suppressed HIV. Conducted in South Africa through three prospective studies, this investigation provides crucial insights into how prebiotics might modulate iron absorption and loss, potentially revolutionizing nutritional interventions in immunocompromised pediatric populations.

Iron deficiency remains one of the most pervasive nutritional disorders worldwide, disproportionately affecting children in regions burdened by infectious diseases such as HIV. While antiretroviral therapies have successfully managed viral loads, the interplay between iron metabolism and HIV suppression remains underexplored, especially considering iron’s dualistic role in host immunity and pathogen growth. Addressing these complexities, the study spearheaded by Baumgartner and colleagues meticulously evaluated iron dynamics in children whose HIV infections were effectively suppressed.

Employing state-of-the-art isotopic techniques, researchers were able to precisely quantify iron absorption rates and systemic loss, providing an unprecedented resolution of iron kinetics in this unique demographic. This methodological advancement beyond conventional hematological markers allows for a nuanced understanding of iron homeostasis affected by chronic viral infection and therapeutic regimens.

One of the critical questions addressed was whether prebiotic supplementation, known for modulating gut microbiota and enhancing nutrient bioavailability, could augment iron uptake in these children. The gut microbiome’s role in regulating iron metabolism is increasingly recognized, with prebiotics posited to create a more favorable intestinal milieu for iron absorption through selective bacterial proliferation and metabolic byproducts.

Findings revealed that prebiotics paired with iron supplementation significantly enhanced iron absorption compared to iron supplementation alone. This enhancement was likely mediated by the prebiotic-induced improvements in gut barrier function and microbiome composition, which collectively reduce inflammation and oxidative stress, both known impediments to effective iron uptake.

Moreover, the study carefully documented iron loss parameters, highlighting that children with virally suppressed HIV exhibited distinctive profiles in systemic iron retention and mobilization. These profiles have critical implications for tailoring supplementation doses to circumvent iron overload risks while alleviating deficiency states.

Transitioning from the biological mechanisms to clinical applicability, this comprehensive investigation underscores the necessity of integrated approaches combining antiretroviral therapy with targeted nutritional strategies that include prebiotics. Such interventions promise to not only normalize iron status but also potentially improve overall health outcomes by reinforcing gastrointestinal integrity and immune competence.

Importantly, the safety profile of iron plus prebiotic supplementation was thoroughly assessed and found to be favorable, with no significant adverse effects reported over the study periods. This finding alleviates longstanding concerns regarding iron fortification in populations at risk for infections, where iron could inadvertently fuel pathogenic proliferation.

Furthermore, this work contributes to bridging gaps in global health policies by informing guidelines that recommend context-specific supplementation protocols for children living with HIV, particularly in sub-Saharan Africa, where the dual burden of HIV and micronutrient deficiencies is profound.

The prospective design of these studies, encompassing longitudinal assessments across diverse pediatric cohorts, bolsters the robustness of the conclusions. It also paves the way for future research integrating multi-omics analyses to delineate the mechanisms underlying iron metabolism’s alterations in chronic viral infection better.

From a broader perspective, the elucidation of how prebiotics impact iron absorption extends beyond HIV contexts, potentially affecting management strategies for other chronic diseases marked by inflammation and malabsorption syndromes. This interdisciplinary relevance elevates the significance of the study in the nutritional science and infectious disease research domains.

Taken together, the study by Baumgartner et al. sets a new benchmark in understanding iron supplementation dynamics amidst viral suppression, advocating for innovative, adjunctive nutritional therapies that can be seamlessly integrated into existing HIV care frameworks. As such, it represents a paradigm shift toward personalized nutrition that harmonizes with antiretroviral treatment, optimizing pediatric patient outcomes comprehensively.

In conclusion, these findings advocate for clinicians and policymakers to recalibrate iron supplementation protocols by considering the synergistic benefits of prebiotic co-administration, especially in resource-limited settings burdened by pediatric HIV. Future translational research should aim to fine-tune these interventions, explore mechanistic pathways in greater detail, and quantify long-term health impacts.

The research community awaits the replication and expansion of these findings through larger-scale trials, which could affirm the transformative potential of integrating microbiome-focused dietary additives into the standard care of children living with HIV globally.

Subject of Research: Iron absorption and loss dynamics, and the efficacy of iron supplementation with and without prebiotics in children with virally suppressed HIV.

Article Title: Iron absorption and loss, and efficacy of iron supplementation with and without prebiotics in children with virally suppressed HIV: three prospective studies in South Africa.

Article References: Baumgartner, J., Blaauw, R., Mikulic, N. et al. Iron absorption and loss, and efficacy of iron supplementation with and without prebiotics in children with virally suppressed HIV: three prospective studies in South Africa. Nat Commun 16, 9929 (2025). https://doi.org/10.1038/s41467-025-64998-4

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-025-64998-4

Tryptophan, known for its multifaceted biological roles, serves as a precursor for crucial molecules such as serotonin and melatonin, influencing neurological pathways and immune modulation. The notable depletion of tryptophan discovered in the breast milk of mothers living with HIV suggests a systemic alteration in amino acid metabolism triggered by chronic viral infection and immune activation. Given that approximately 1.3 million children worldwide are born annually to women living with HIV, the metabolic deficiency highlighted by this research may illuminate the underlying causes of increased morbidity and developmental impairments observed in these infants, despite effective prevention of vertical viral transmission.

Historically, children born to mothers with HIV but uninfected themselves have experienced elevated mortality rates and increased susceptibility to infections, growth failure, and cognitive delays, with mortality in low-resource settings reaching up to twice or thrice that of infants born to uninfected mothers prior to the advent of widespread antiretroviral therapy (ART). Intriguingly, even with the implementation of ART, these disparities persist, suggesting that viral suppression alone does not fully mitigate the metabolic disruptions or the inflammatory milieu affecting infant health. Until now, the biochemical and metabolic mechanisms contributing to these outcomes remained poorly understood, underscoring the significance of the present study’s metabolomic approach.

The UCLA team meticulously analyzed a vast repository of breast milk samples collected longitudinally from Zambian women enrolled in a clinical trial that spanned seven years, encompassing both HIV-positive and HIV-negative cohorts. Utilizing state-of-the-art metabolomic profiling techniques, over 800 distinct metabolites were quantified at multiple postpartum intervals, ranging from the neonatal stage through 18 months of lactation. To enhance the robustness of their conclusions, researchers conducted parallel validation in an independent cohort from Haiti, where all HIV-positive participants were undergoing antiretroviral treatment with improved immunologic profiles.

Findings revealed a consistent approximate 50% reduction in tryptophan concentrations in breast milk from HIV-positive mothers compared to controls across all time points. Moreover, an elevated kynurenine-to-tryptophan ratio was observed, a well-established biomarker indicative of heightened immune activation and indoleamine 2,3-dioxygenase (IDO) enzyme activity—a metabolic pathway often upregulated during chronic viral infections and systemic inflammation. These metabolic alterations in the milk were mirrored by decreased plasma tryptophan levels in the mothers, signifying that the depletion is not isolated to the mammary compartment but reflects a broader systemic deficiency possibly mediated by impaired intestinal absorption and sustained immune activation.

In addition to tryptophan metabolism perturbations, the research identified elevated levels of novel antiviral metabolites such as ddhC (3′-deoxy-3′,4′-didehydro-cytidine) alongside increased cytosine and dimethylarginine concentrations in the breast milk of women living with HIV. These molecules are biologically linked to chronic interferon signaling and innate immune responses, further corroborating the presence of persistent viral inflammation despite ART administration. Notably, these profound metabolic fingerprints persisted in the Haitian cohort, affirming their relevance and stability in the context of contemporary HIV therapy and enhanced immune status.

These insights into the altered amino acid metabolism and antiviral metabolite profiles raise compelling questions about the consequences for infant health and development. Tryptophan serves not only as a substrate for protein synthesis but also as a modulator of immune tolerance and neurodevelopmental processes. Deficiencies during critical windows of postnatal growth could underlie the increased incidence of infections, stunted growth, and neurocognitive impairments reported in HIV-exposed uninfected children. The kynurenine pathway metabolites, some of which exhibit neurotoxic properties, may further compound these risks, highlighting the delicate balance between immune activation and metabolic homeostasis in shaping infant outcomes.

Looking forward, the UCLA team stresses caution in translating these findings into clinical practice, emphasizing the complexities of tryptophan metabolism and its downstream pathways. Simple supplementation of tryptophan might inadvertently exacerbate neurotoxic metabolite accumulation if not coupled with interventions targeting the inflammatory cascade and enzymatic dysregulation. Ongoing and future studies will leverage animal models replicating chronic viral inflammation to investigate the safety and efficacy of potential nutritional interventions aimed at restoring metabolic equilibrium, enhancing immune resilience, and promoting optimal cognitive and physiological development in HIV-exposed infants.

Moreover, parallel research endeavors are planned to delineate whether infants born to mothers living with HIV experience systemic tryptophan depletion and altered metabolic processing—a critical extension that may uncover direct metabolic vulnerabilities in this population. Should nutritional or pharmacological strategies prove effective in these investigations, they could revolutionize neonatal care paradigms for the 1.3 million children exposed to HIV annually, reducing disproportionately high rates of morbidity and mortality in regions burdened by the HIV epidemic.

Reflecting on the broader implications, Dr. Grace Aldrovandi, corresponding author and professor at UCLA’s David Geffen School of Medicine, articulates that this study marks a seminal step in understanding the biological underpinnings that link maternal HIV infection to adverse infant health outcomes beyond viral transmission alone. Dr. Aldrovandi highlights that these metabolic insights open novel avenues for therapeutic innovation targeting not the virus per se, but the metabolic and immunologic sequelae that persist despite effective viral suppression. Complementing this perspective, Dr. Nicole Tobin, the study’s lead author, underscores the enduring nature of the metabolic signature, evident despite modern ART, and its explanatory power regarding the continuing disparities faced by these children. Together, these expert interpretations signal a paradigm shift in HIV maternal-child health research, emphasizing metabolic restoration as a frontier for improving long-term outcomes.

In conclusion, this landmark research elucidates a previously unappreciated dimension of HIV pathophysiology—chronic systemic and localized metabolic dysregulation manifesting in lactational biology—and its profound ramifications for infant health. By identifying tryptophan deficiency and heightened immune-metabolic activation in breast milk, the study provides a metabolic explanation for the lingering vulnerabilities of HIV-exposed but uninfected children. Continued interdisciplinary efforts integrating metabolomics, immunology, nutrition, and clinical medicine hold promise for developing targeted interventions that could transform the lives of millions of children born into the context of maternal HIV worldwide.

Subject of Research: People

Article Title: Altered milk tryptophan and tryptophan metabolites in women living with HIV

News Publication Date: 28-Oct-2025

Web References: https://doi.org/10.1038/s41467-025-64566-w

Keywords: Human immunodeficiency virus, Breast feeding